Torrent Pharmaceuticals revenue and financials
₹4,778.00Change from previous close: +0.48%Absolute change: +₹22.85
In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹139.8B (+21.39% year over year). Net income was ₹21.63B, a net margin of 15.5%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.39%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +13.19%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 15.5%
- FY to Mar 2025: 16.6%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total revenue | 139,797 | 115,161 | 107,278 | 96,202 | 85,080 |
| Cost of revenue | 33,882 | 27,759 | 26,862 | 27,352 | 24,420 |
| Gross profit | 105,916 | 87,402 | 80,416 | 68,850 | 60,660 |
| Selling, general and administrative | 27,313 | 22,708 | 20,166 | 17,052 | 15,483 |
| Research and development | 450 | 304 | 247 | 313 | — |
| Operating income | 34,398 | 29,261 | 25,724 | 21,400 | 17,693 |
| EBIT | 34,398 | 29,261 | 25,724 | 21,400 | 17,693 |
| EBITDA | 44,968 | 36,758 | 33,249 | 28,026 | 23,823 |
| Interest expense | 3,847 | 2,514 | 3,526 | 3,322 | 2,529 |
| Pre-tax income | 28,722 | 26,728 | 23,521 | 18,472 | 12,259 |
| Income tax | 7,340 | 7,616 | 6,957 | 6,019 | 4,487 |
| Net income | 21,634 | 19,113 | 16,564 | 12,452 | 7,772 |
| Net income to common shareholders | 21,634 | 19,113 | 16,564 | 12,452 | 7,772 |
| Basic EPS | 63.92 | 56.47 | 48.94 | 36.79 | 22.96 |
| Diluted EPS | 63.92 | 56.47 | 48.94 | 36.79 | 22.96 |
| Average shares (basic) | 338 | 338 | 338 | 338 | 338 |
| Average shares (diluted) | 338 | 338 | 338 | 338 | 338 |
| Dividend per share | 38.00 | 32.00 | 28.00 | 22.00 | 16.50 |